Notification Detail

This draft Commission Implementing Decision repeals the postponement of the expiry date of the approval of dazomet as an active substance for use in biocidal products of product type 8.On 26 January 2021, an application was submitted in accordance with Article 13(1) of the Regulation (EU) No 528/2012 of the European Parliament and of the Council (BPR) for the renewal of the approval of dazomet for PT8. On 25 February 2025 the Agency adopted its opinion on dazomet for PT8, having regard to the conclusions of the evaluating competent authority.Given the opinion of the Agency, it is appropriate to renew the approval of dazomet for PT8. Consequently, a draft Implementing Regulation is being prepared to renew the approval of dazomet for PT8 (examination procedure under Regulation (EU) No 182/2011).Further to that Implementing Regulation, it is necessary to repeal the postponement of the expiry date of the approval of dazomet. The present draft Decision therefore intends to repeal Decision (EU) 2024/2930 postponing the expiry date of the approval of dazomet for PT8.